A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

Inclusion Criteria

• Inclusion Criteria:
• -Must have suitable veins for cannulation or repeated venipuncture.
• -Female(s) of Childbearing Potential must use adequate contraception (oral contraceptives are not permitted).
• -Have a BMI ≥ 23 kg/m2 and not exceeding 35 kg/m2 inclusive and weigh at least 60 kg.
• -No or off statin treatment for ≥ 4 weeks prior to the study treatment.
• Exclusion Criteria:
• -History of any clinically important disease or disorder.
• -History of acute pancreatitis, chronic pancreatitis, gallstones, or elevation in serum lipase/pancreatic amylase.
• -History or presence of gastrointestinal, hepatic, or renal disease.
• -Clinically significant hepatic disease, inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal tract.
• -Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
• -Any clinically important abnormalities in rhythm, blood pressure, heart rate,
• conduction or morphology of the resting electrocardiogram (ECG).
• -Uncontrolled thyroid disease, defined as thyroid-stimulating hormone > 6.0 mIU/L or < 0.4 mIU/L at Screening.
• -Current smokers or known history of alcohol or drug abuse.
• -History of severe allergy/hypersensitivity or excessive intake of caffeine-containing drinks or food.
• -Use of any prescribed or nonprescribed medication including antacids or analgesics.
• -Participants who are on or are planning to undertake a weight loss program.
• -History of psychosis, major depressive disorder, suicide attempt or suicidal ideation within the past year.
• -Lactating, breastfeeding, or pregnant females or females who intend to become pregnant.
• -Participants who are vegans or have medical dietary restrictions.